This study seeks to determine imaging characteristics of radiolabelled 131-I-NM404 in ten
patients with cancer, including calculations of PKs, radiation dosimetry, biodistribution,
and optimal imaging times (part 1 - complete).
In addition, specific tumor accumulation and metabolic fate of 131-I-NM404 will be determined
in NSCLC tumors collected in 5 patients (part 2 - complete). Lastly, the study will collect
preliminary data on imaging NSCLC tumors in up to 12 patients with evaluable disease (part 3
- ongoing).
Phase:
Phase 1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
Cellectar Biosciences, Inc. National Cancer Institute (NCI)